Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. - Wikidata - wikimedia - TriplyDB

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.

http://www.wikidata.org/entity/Q34655367

about

Structured telephone support or telemonitoring programmes for patients with chronic heart failure Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials Heart Failure: Diagnosis, Management and Utilization What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group Right ventricular afterload and the role of nitric oxide metabolism in left-sided heart failure Agents with vasodilator properties in acute heart failure: how to design successful trials Addressing the Heterogeneity of Heart Failure in Future Randomized Trials.Tezosentan normalizes hepatomesenteric perfusion in a porcine model of cardiac tamponade.Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.Stimuli of sensory-motor nerves terminate arterial contractile effects of endothelin-1 by CGRP and dissociation of ET-1/ET(A)-receptor complexes Neurohormonal profile of patients with heart failure and diabetes Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study.International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes.Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics Diuretic use in heart failure and outcomes.Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides.Nuclear translocation of cardiac G protein-Coupled Receptor kinase 5 downstream of select Gq-activating hypertrophic ligands is a calmodulin-dependent process.In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group.Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies.De novo acute heart failure and acutely decompensated chronic heart failure Antidiuretic effects of the endothelin receptor antagonist avosentan.Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF)Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial.The Impact of Worsening Heart Failure in the United States Differences in health care use and outcomes by the timing of in-hospital worsening heart failure.Evaluation of a provocative dyspnea severity score in acute heart failure.Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research.Early and long-term outcomes of heart failure in elderly persons, 2001-2005.Overview of emerging pharmacologic agents for acute heart failure syndromes.Role of tolvaptan in acute decompensated heart failure.Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF Pharmacotherapy for meconium aspiration.Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?Effects of tolvaptan on dyspnoea relief from the EVEREST trials.Timing and duration of interventions in clinical trials for patients with hospitalized heart failure.

P2860

Q24236592-7EC24195-8175-4484-B657-C4048A7CC210 Q24650348-87A8FA63-9B93-4621-8C67-0D5CD9C2AC7D Q26745543-A550B033-E8B8-45B7-A765-EE08581F4AAE Q26771479-5786FF77-55C9-4F5A-AC6B-D41C0C53225F Q26800965-2217F7F2-FF5B-4A77-BFBC-0ED0632DFB65 Q27000455-9C942857-2781-48D8-9CC7-EA4FE74BEFC6 Q27022359-8D3C85B6-1931-42FB-9204-29E5345C4398 Q28084239-D148675F-EC3A-4B08-B00C-5EB3CF0DBABC Q30234708-299BB430-421C-49AB-B9E3-E7884C8ED495 Q33394352-8D6F83B9-2F0A-4B72-A461-5CB1E3FD013D Q33529398-AE6755A1-1AFE-4894-9247-5049657DA4A0 Q33598651-C714B85B-0163-407B-BD5F-2071A6D95254 Q33799053-B3B7130E-C9A5-4D54-BF20-68E6353E821C Q33845755-12208FB3-283F-43CC-95AE-F46E7E88A611 Q33973976-A31E9DDF-7428-4682-8986-1396AF5AF15F Q34148325-1126F553-22B1-444E-AFCD-667AB8BE9DDC Q34308342-2C480E1A-7ACD-4D93-B82E-A6AAD1DCEBE8 Q34344390-31BFE2FC-982F-4B2F-A216-2591A615DA37 Q34357452-602234FF-E90E-45A3-9B5A-44CB835700F8 Q34481884-A4E5D5F3-400A-442D-A302-07B3A8825469 Q34614326-B829F593-3FE1-4F5A-99A3-A8A79C526036 Q35026394-2E8AFD85-5B54-46B7-A518-FAE947033E89 Q35057622-24FEC080-D199-4C42-8F00-5170F5089687 Q35203569-4CDD49A9-8986-43C6-A6E0-4EAB96623085 Q35675983-8032DF26-FC8D-4C06-BFFE-0883441EAC16 Q35895257-D72B789A-12D8-44F5-8BB8-0ABAF6C97F45 Q36089337-73EF5671-37D3-4B83-95B1-BB8EAA0943B2 Q36158310-05C80B12-E024-410E-ADB1-11E3A263C708 Q36168137-59790EAE-E24E-45BF-ADB3-3C4D9E4F1C69 Q36385581-BDB585CE-EE5C-450C-9DA9-EBE5EF421773 Q36564895-546199D0-B2C1-4215-A0F0-F60B9E392E0E Q36868978-81865CE1-7943-4C07-8A88-4F4B621C9E5F Q37067936-243F6311-D7AC-4C26-ABD6-944023A81E95 Q37086309-58DE7C2C-3B0B-4B8F-A70B-6541967E38B6 Q37176415-97620919-5F5A-4757-8F38-83AB55B84BEE Q37240303-725C471B-8DB7-424F-8C70-7656EB8E3A07 Q37341679-4F1F9FCE-5442-4E1B-8551-9B4624443E1A Q37343008-14B5D030-2F14-492D-9873-B4EE419228C0 Q37343857-0C1D4062-4089-403C-AC37-BCF8AD6FEEC0 Q37354429-3001823D-C82F-4B38-B6F5-C9BBD662C887

P2860

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.

http://www.wikidata.org/entity/Q34655367

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Effects of tezosentan on sympt ...... randomized controlled trials.

@ast

Effects of tezosentan on sympt ...... randomized controlled trials.

@en

Effects of tezosentan on sympt ...... randomized controlled trials.

@nl

type

label

Effects of tezosentan on sympt ...... randomized controlled trials.

@ast

Effects of tezosentan on sympt ...... randomized controlled trials.

@en

Effects of tezosentan on sympt ...... randomized controlled trials.

@nl

prefLabel

Effects of tezosentan on sympt ...... randomized controlled trials.

@ast

Effects of tezosentan on sympt ...... randomized controlled trials.

@en

Effects of tezosentan on sympt ...... randomized controlled trials.

@nl

P1433

Q34655367-9D499834-3F83-455D-8D43-9F5B0A8FDEF8

P1476

Q34655367-6D6DB9BE-8DFE-46CE-B321-10530B2850E1

P2093

Q34655367-1C312B93-3B44-4BB0-ACF0-B4342EB9916A

Q34655367-3E6C6123-7436-42D4-876E-55092F910A5C

Q34655367-5AF04560-5BBB-4AA0-B32C-FF153481D55E

Q34655367-713B3E5D-8A62-4D83-BBF3-39731E6757A9

Q34655367-9A78AECC-6644-42D6-90B0-4E71F017CC3B

Q34655367-9F8ECFE6-02B1-433F-BA9C-04CA1DD4B2E7

Q34655367-A66D9ED7-22C4-4F8B-95E3-A5716778FDEC

Q34655367-BA330442-0EF9-4339-8821-31AA284F91AA

Q34655367-D26694AB-C169-4642-9FCA-61BEB04FA618

Q34655367-D32A985E-86A3-4519-A882-5108D9F1AEFC

P304

Q34655367-95BBF42C-9072-45C7-BB31-A30650D7414A

P31

Q34655367-AB6E1ED4-01B7-4A9C-AD9C-4D35DD18C88D

P356

Q34655367-BD01369B-8087-499F-9EED-8AFD714D1C1D

P407

Q34655367-2B46EDFE-1B85-4567-BA1C-E9A0B5D51515

P433

Q34655367-70151439-463B-4637-B23F-08A5D6394868

P478

Q34655367-5056AAFB-78DF-47FC-919D-1166FED8AA0A

P50

Q34655367-79964338-12F3-44A6-81D4-70782B13236C

Q34655367-83CF67B4-6A8C-46D3-A095-AFF2518C8AC3

Q34655367-95027885-92A0-43FA-9481-126C064AF0CC

Q34655367-B85C0608-A91D-4286-BED2-613CBC807DDD

Q34655367-EC4FFCCD-E9F8-4C77-BFC4-E71E12829A82

P577

Q34655367-DFA47228-9277-43F1-8875-19B21EAE3A65

P698

Q34655367-74327D6C-721F-41E0-AC87-596D3E26E088

P921

Q34655367-019713BF-9D6D-4762-9D4A-C364F0A6A35A

Q34655367-27DEC981-85B4-49A3-B486-B3828606DF0F

P356

JAMA.298.17.2009

P1433

Journal of the American Medical Association

P1476

Effects of tezosentan on sympt ...... randomized controlled trials.

@en

P2093

Aline Frey

http://www.w3.org/2001/XMLSchema#string

Gadi Cotter

http://www.w3.org/2001/XMLSchema#string

Guillaume Jondeau

http://www.w3.org/2001/XMLSchema#string

Guillermo Torre-Amione

http://www.w3.org/2001/XMLSchema#string

Isaac Kobrin

http://www.w3.org/2001/XMLSchema#string

Jim Lewsey

http://www.w3.org/2001/XMLSchema#string

John G F Cleland

http://www.w3.org/2001/XMLSchema#string

John J V McMurray

http://www.w3.org/2001/XMLSchema#string

John R Teerlink

http://www.w3.org/2001/XMLSchema#string

Maurizio Rainisio

http://www.w3.org/2001/XMLSchema#string

P304

2009-2019

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.298.17.2009

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

298

http://www.w3.org/2001/XMLSchema#string

P50

Christopher M O'Connor

Dirk J van Veldhuisen

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17986694

http://www.w3.org/2001/XMLSchema#string

P921